tbuckley/cabot-search huggingface dataset:
Impact of Pre-Transplant Molecular and Cytogenetic Remission on Outcomes of Allogeneic Stem Cell Transplant in Patients with Myelodysplastic Syndrome
Authors: Shivani Handa, Namrata Sonia Chandhok, Sudhamsh Reddy Desai, Asem Berkalieva, Erin Moshier, Douglas Tremblay, Lewis R. Silverman, Trent Wang, Uroosa Ibrahim, Aditi Shastri, Jonathan Feld
Journal: Blood (2023)
Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma
Authors: Leo Meriranta, Maare Arffman, Judit Mészáros Jørgensen, Harald Holte, Kristina Drott, Henrikki Almusa, Emma Saarinen, Sari Hannula, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Sirpa Leppä
Journal: Blood (2023)
Minimal Residual Disease Detection By Single Cell DNA Sequencing Technology: A Feasible Approach for Clinical Application and Identification of the Landscape of MRD Clones
Authors: Ana Alfonso Pierola, Beñat Ariceta, Amaia Vilas-Zornoza, Paula Aguirre-Ruiz, Sarai Sarvide, Patxi San-Martin, Maria-Antonia Fortuño, Catia Simoes, Leire Burgos, Maria Jose Larrayoz, Carmen Chillon, Olga Arce, Teresa Bernal Del Castillo, Mercedes Colorado, Laida Cuevas Palomares, Inmaculada Marchante, Maria Carmen Mateos, Mayte Olave, Jose A. Pérez-Simón, Maria Jose Calasanz, Ramon Garcia-Sanz, Bruno Paiva, Pau Montesinos, Felipe Prosper
Journal: Blood (2023)
Defective Clearance of Neutrophils Causes Pathogenic Microenvironmental Interactions and Offers a Candidate Immunotherapy in the Myeloproliferative Neoplasms
Authors: Eman Khatib-Massalha, Ya-Hsuan Ho, Elodie Grockowiak, Yuki Date, Lam Tan Khuat, Zijian Fang, Eva Carrillo Félez, Christian Di Buduo, Alessandra Balduini, Simón Méndez-Ferrer
Journal: Blood (2023)
Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients from Clinical Trial NCT02513186
Authors: Luciano Di Stefano, Zarouki Mouktadi, Victor Vimard, Sarah Moreau, Sandrine Mace, Zandra K. Klippel, Vincent Bonifay, Caroline Rougé Dubroc, Pierre Sonigo
Journal: Blood (2023)
Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial
Authors: Fadi G. Haddad, Elias Jabbour, Nicholas J. Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Cedric Nasnas, Ejiroghene Mayor, Patrice Eric Nasnas, Wuliamatu Deen, Marianne Zoghbi, Jennifer Thankachan, Christopher Loiselle, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood (2023)
Outcomes of Veterans Treated in Veterans Affairs Hospitals vs Non–Veterans Affairs Hospitals
Authors: Jean Yoon, Ciaran S. Phibbs, Michael K. Ong, Megan E. Vanneman, Adam Chow, Andrew Redd, Kenneth W. Kizer, Matthew P. Dizon, Emily Wong, Yue Zhang
Journal: JAMA Network Open (2023)

Many veterans enrolled in the Veterans Affairs (VA) health care system have access to non-VA care through insurance and VA-purchased community care. Prior comparisons of VA and non-VA hospital outcomes have been limited to subpopulations.To compare outcomes for 6 acute conditions in VA and non-VA hospitals for younger and older veterans using VA and all-payer discharge data.This cohort study used a repeated cross-sectional analysis of hospitalization records for acute myocardial infarction (AMI), coronary artery bypass graft (CABG), gastrointestinal (GI) hemorrhage, heart failure (HF), pneumonia, and stroke. Participants included VA enrollees from 11 states at VA and non-VA hospitals from 2012 to 2017. Analysis was conducted from July 1, 2022, to October 18, 2023.Treatment in VA or non-VA hospital.Thirty-day mortality, 30-day readmission, length of stay (LOS), and costs. Average treatment outcomes of VA hospitals were estimated using inverse probability weighted regression adjustment to account for selection into hospitals. Models were stratified by veterans' age (aged less than 65 years and aged 65 years and older).There was a total of 593 578 hospitalizations and 414 861 patients with mean (SD) age 75 (12) years, 405 602 males (98%), 442 297 hospitalizations of non-Hispanic White individuals (75%) and 73 155 hospitalizations of non-Hispanic Black individuals (12%) overall. VA hospitalizations had a lower probability of 30-day mortality for HF (age ≥65 years, -0.02 [95% CI, -0.03 to -0.01]) and stroke (age <65 years, -0.03 [95% CI, -0.05 to -0.02]; age ≥65 years, -0.05 [95% CI, -0.07 to -0.03]). VA hospitalizations had a lower probability of 30-day readmission for CABG (age <65 years, -0.04 [95% CI, -0.06 to -0.01]; age ≥65 years, -0.05 [95% CI, -0.07 to -0.02]), GI hemorrhage (age <65 years, -0.04 [95% CI, -0.06 to -0.03]), HF (age <65 years, -0.05 [95% CI, -0.07 to -0.03]), pneumonia (age <65 years, -0.04 [95% CI, -0.06 to -0.03]; age ≥65 years, -0.03 [95% CI, -0.04 to -0.02]), and stroke (age <65 years, -0.11 [95% CI, -0.13 to -0.09]; age ≥65 years, -0.13 [95% CI, -0.16 to -0.10]) but higher probability of readmission for AMI (age <65 years, 0.04 [95% CI, 0.01 to 0.06]). VA hospitalizations had a longer mean LOS and higher costs for all conditions, except AMI and stroke in younger patients.In this cohort study of veterans, VA hospitalizations had lower mortality for HF and stroke and lower readmissions, longer LOS, and higher costs for most conditions compared with non-VA hospitalizations with differences by condition and age group. There were tradeoffs between better outcomes and higher resource use in VA hospitals for some conditions.
Real-World Applications of Guideline Based Diagnostic and Treatment Patterns for Diffuse Large B-Cell Lymphoma within the Veterans Health Administration (VHA)
Authors: Amna Naqvi, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean-Pierre Blaize, Snegha Ananth, Michael Meansup Song, Brian Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Lindsey Lu, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia Lee, Gabriel Roman Souza, Esteban Toro Velez, Ian Mines, Zohra Nooruddin
Journal: Blood (2023)
Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study
Authors: Leyre Bento, Antonio Gutiérrez, Carmen Martínez, Consejo Ortí, Marina Sorribes, Ana Carolina Caballero, Marta Peña, Ariadna Pérez, Ana Jimenez Ubieto, Mariana Bastos-Oreiro, Paula Fernández Caldas-González, Belén Navarro, Isabel Salcedo, Pau Abrisqueta Costa, Ignacio Español, Javier Cornago, Fernando Martín-Moro, Lucía García, Pilar Gómez, Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González, Pedro Gonzalez-Sierra, Cristina Blázquez Goñi, Jordina Rovira, Marta Sitges, Mireia Franch, Almudena Cabero, Alberto Mussetti, Juan Montoro, Antonia Sampol Mayol, Anna Maria Sureda Balari, Dolores Caballero, Alejandro Martín García-Sancho
Journal: Blood (2023)
Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity
Authors: Dominik Awad, Pham Hong Anh Cao, Thomas L. Pulliam, Meredith Spradlin, Elavarasan Subramani, Tristen V. Tellman, Caroline F. Ribeiro, Riccardo Muzzioli, Brittany E. Jewell, Hubert Pakula, Jeffrey J. Ackroyd, Mollianne M. Murray, Jenny J. Han, Mei Leng, Antrix Jain, Badrajee Piyarathna, Jingjing Liu, Xingzhi Song, Jianhua Zhang, Albert R. Klekers, Justin M. Drake, Michael M. Ittmann, Cristian Coarfa, David Piwnica-Worms, Mary C. Farach-Carson, Massimo Loda, Livia S. Eberlin, Daniel E. Frigo
Journal: Cancer Research (2023)

Lipid metabolism plays a central role in prostate cancer. To date, the major focus has centered on de novo lipogenesis and lipid uptake in prostate cancer, but inhibitors of these processes have not benefited patients. A better understanding of how cancer cells access lipids once they are created or taken up and stored could uncover more effective strategies to perturb lipid metabolism and treat patients. Here, we identified that expression of adipose triglyceride lipase (ATGL), an enzyme that controls lipid droplet homeostasis and a previously suspected tumor suppressor, correlates with worse overall survival in men with advanced, castration-resistant prostate cancer (CRPC). Molecular, genetic, or pharmacologic inhibition of ATGL impaired human and murine prostate cancer growth in vivo and in cell culture or organoids under conditions mimicking the tumor microenvironment. Mass spectrometry imaging demonstrated that ATGL profoundly regulates lipid metabolism in vivo, remodeling membrane composition. ATGL inhibition induced metabolic plasticity, causing a glycolytic shift that could be exploited therapeutically by cotargeting both metabolic pathways. Patient-derived phosphoproteomics identified ATGL serine 404 as a target of CAMKK2-AMPK signaling in CRPC cells. Mutation of serine 404 did not alter the lipolytic activity of ATGL but did decrease CRPC growth, migration, and invasion, indicating that noncanonical ATGL activity also contributes to disease progression. Unbiased immunoprecipitation/mass spectrometry suggested that mutation of serine 404 not only disrupts existing ATGL protein interactions but also leads to new protein-protein interactions. Together, these data nominate ATGL as a therapeutic target for CRPC and provide insights for future drug development and combination therapies.
Unraveling the Dynamics of T Cell-Dependent Bispecific Antibodies in Multiple Myeloma: Multi-Omic Insights from Primary Patient Cells
Authors: Dennis J Wu, Amy S Chen, Nikki Deangelis, Diana Cortes, Jose Morachis, Benjamin Titz, Sylvaine Cases, Raluca Verona, Chorom Pak
Journal: Blood (2023)
Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, in Combination with Costimulatory Blockers Delayed Skin Graft Rejection in Mice
Authors: Audrey Le Floch-Ramondou, George Scott, Wen-Chi Chen, Kirsten Nagashima, Andrew Murphy, Matthew Sleeman, Jamie Orengo
Journal: Blood (2023)
Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study
Authors: Alissa Visram, Kelvin KW Chan, Hsien Seow, Gregory Pond, Ana Gayowsky, Arleigh McCurdy, Irwindeep Sandhu, Christopher P. Venner, Guido Lancman, Amaris Balitsky, Robert Bruins, Shaji Kunnathu Kumar, Rafael Fonseca, Hira Mian
Journal: Blood (2023)
Deciphering Transcriptomic and (Epi)Genetic Signatures of Central Nervous System Infiltration in Patients Diagnosed with Diffuse Large B-Cell Lymphoma
Authors: Carlota Pages-Geli, Sabela Bobillo, Pau Abrisqueta, Josep Castellvi, Laura Palomo, Damiana Alvarez, Manel Esteller, Francesc Bosch, Marta Crespo
Journal: Blood (2023)
Primary Immune Regulatory Disorders (PIRDs) That Amplify mTOR Signaling Share a T Cell Exhaustion-like Process
Authors: Peyton E Conrey, Jose Campos, Andrea Mauracher, Samir Sayed, Jolan E. Walter, Helen Su, Sara Barmettler, Jennifer W Leiding, Megan Cooper, Suzanne P MacFarland, Melanie A Ruffner, Jocelyn R Farmer, V. Koneti Rao, Sarah E Henrickson
Journal: Blood (2023)
Exposure to Fine Particulate Matter (PM2.5) Is Associated with Worse Multiple Myeloma Outcomes in a Large, Urban, Multi-Ethnic Cohort
Authors: Michael Wysota, Sarah Jacobs, Kith Pradhan, Joel Rosiene, Charles Hall, George Downward, Yocheved Halberstam, Nishi Shah, Dean Hosgood, Aditi Shastri
Journal: Blood (2023)
Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study
Authors: Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro
Journal: Blood (2023)
CDCA2 Is a Predictive Marker and Mediator of Bortezomib Response in Diffuse Large B-Cell Lymphoma
Authors: Hanne Due, Issa Ismail Issa, Martin Thomsen, Maja Zimmer Jakobsen, Hulda Haraldsdóttir, Rasmus Froberg Brøndum, Karen Dybkaer
Journal: Blood (2023)
Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study
Authors: Nicole Fabbri, Marta Peña, Pere Barba, Gloria Iacoboni, Mi Kwon, Rebeca Bailen, Jose A. Perez-Simon, Javier Delgado, Lucia Lopez Corral, Ana Africa Martin Lopez, Rafael Hernani, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Manuel Guerreiro, Jaime Sanz, Ana Carolina Caballero Gonzalez, Juan-Manuel Sancho, Lucrecia Yanez San Segundo, Anabelle Chinea, Jose Sanchez-Pina, Maria Del Mar Perera Alvarez, Blanca Rius-Sansalvador, Anna Maria Sureda Balari, Alberto Mussetti
Journal: Blood (2023)
18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma
Authors: Doris Leithner, Jessica R. Flynn, Sean M. Devlin, Audrey Mauguen, Teng Fei, Shang Zeng, Brandon S. Imber, Harper Hubbeling, Marius Mayerhoefer, Efrat Luttwak, Magdalena Corona, Parastoo Bahrami Dahi, Alejandro Luna De Abia, Ivan Landego, Richard J. Lin, Maria Lia Palomba, Michael Scordo, Ana Alarcon Tomas, Gilles Salles, Daniel Lafontaine, Laure Michaud, Gunjan L. Shah, Miguel-Angel Perales, Heiko Schoder, Roni Shouval
Journal: Blood (2023)
Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials
Authors: Keshu Zhou, Mingyuan Sun, Xu Wei, Shuhua Yi, Junyuan Qi, Weiqi Nian, Guohui Cui, Jishi Wang, Xiaoping Zhang, Hong Cen, Fuling Zhou, Jianying Huang, Huilan Liu, Aizong Shen, Liangquan Geng, Ru Feng, Chongyuan Xu, Wenbin Qian, Fei Li, Lihong Liu, Caixia Li, Xielan Zhao, Jie Jin, Hongmei Jing, Dongmei Ji, Fangfang Lyu, Zi Chen, Lichuang Men, Hengbang Wang, Ke Zhang, Liang Xu, Zhang Zhang, Dajun Yang, Jianxiang Wang, Jianyong Li, Yifan Zhai
Journal: Blood (2023)
Post CAR-T Peripheral Lymphocytosis and Its Kinetics Are a Potential Biomarker for Response and Immune Mediated Toxicities
Authors: Mateo Mejia Saldarriaga, Caitlin Unkenholz, Joshua A Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, Markus Mapara, Giorgio Inghirami, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros
Journal: Blood (2023)
Venous Thromboembolism Outcomes Among Cancer and Non-Cancer Patients Managed with Patient-Centric Guideline-Driven Protocol
Authors: Claire E. Cassianni, Robert D. McBane, Danielle T. Vlazny, David O. Hodge, Ana I. Casanegra, Damon E. Houghton, Waldemar E. Wysokinski
Journal: Blood (2023)
Estimating the Burden of Venous and Arterial Thrombotic Events in Hospitalized Adults with COVID-19; A National Multicenter Cohort Study
Authors: Rushad Patell, Dana E. Angelini, Stacy R Ellsworth, Paul Lewis, James C Lee, Edith A. Nutescu, Alpesh Amin, Daniel M Witt, Marisol Betensky, Neil Goldenberg, Peter Kouides, Doaa Attia, MD, Lyla Mourany, Leslie Lake, Rachel P. Rosovsky, Alok A. Khorana, Scott Kaatz
Journal: Blood (2023)
Cell Free MYC DNA Copy Number Identifies High-Risk Smouldering Myeloma and Newly Diagnosed Multiple Myeloma
Authors: Daniel Wong, John Reynold, Cameron Wellard, Nicholas Bingham, Jessie Zhao, Malarmathy Ramachandran, Hang Quach, Simon Gibbs, Tiffany T. Khong, Sridurga Mithraprabhu, Andrew Spencer
Journal: Blood (2023)
Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions
Authors: Katia Beider, Ilana Kalnitsky, Nira Varda-Bloom, Olga Ostrovsky, Avichai Shimoni, Hila Magen, Arnon Nagler
Journal: Blood (2023)
Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry
Authors: Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Letizia Polito, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio
Journal: Blood (2023)
Obesity after Induction Is Associated with Poor Overall Survival in Adults with Acute Lymphoblastic Leukemia: Results from a Peruvian Adaptation of the CALGB10403 Protocol
Authors: Evelyn Pamela Espinoza Morales, Veronica Y Arnao-Labajos, Juan Carlos Haro-Varas, Bryan Valcarcel, Daniel J Enriquez
Journal: Blood (2023)
<i>ASXL1</i> Mutation and Leukocytosis Undermine Spleen Response to Pacritinib in Myelofibrosis
Authors: Maymona Abdelmagid, Jeanne Palmer, James M. Foran, Aref Al-Kali, Omer Karrar, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood (2023)
Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7
Authors: Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins
Journal: Blood (2023)
Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
Authors: Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood (2023)
Health Care Resource Use, Comorbidities, and Costs of Hemophilia A Patients in France: A Nationwide Claims Database Analysis
Authors: Aurelien Lebreton, Véronique Cahoreau, Nicolas Giraud, Stephanie Delienne, Francis Fagnani, Stéphane Bouée, Juliette Cottin, Isabelle Bureau, Jeremie Rudant, Anais Reynaud, Amelie Coumert, Herve Lilliu, Laurent Frenzel
Journal: Blood (2023)
Hematopoietic Stem Cell Numbers Are Regulated at Both Systemic and Local Levels
Authors: Shoichiro Takeishi, Tony Marchand, Wade R. Koba, Daniel K. Borger, Chunliang Xu, Chandan Guha, Aviv Bergman, Paul S. Frenette, Kira Gritsman, Ulrich Steidl
Journal: Blood (2023)
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients
Authors: Michele Malagola, Alessandra Iurlo, Cristina Bucelli, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Mariella D'Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto Massimo Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Matteo Dalmazzo, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Anna Sicuranza, Aldo Roccaro, Giulia Butturini, Mirko Farina, Simona Bernardi, Simone Pellizzeri, Nicola Polverelli, Domenico Russo
Journal: Blood (2023)
Fourth-Generation HIV Testing
Authors: Michael R. Rose, Natasha M. Chida, Joyce L. Jones
Journal: JAMA (2023)

A 72-year-old man presented to the emergency department with fevers, night sweats, and rash 3 days after condomless vaginal intercourse. Results of a fourth-generation HIV test were positive and HIV-1-/2 antibody differentiation testing was negative. How would you interpret these results?
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States
Authors: Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E. Drolen, Tatyana Feldman, Tarek Haykal, Caroline A. Nebhan, Swetha Kambhampati, Mingjia Li, Arjun Mittra, Michael Lorentsen, Chul Kim, Alexandra Drakaki, Michael Morse, Douglas B. Johnson, Ankit Mangla, Chris Dittus, Praful Ravi, Paul G. Rubinstein, Sarvari V. Yellapragada, Ann LaCasce, Guru P. Sonpavde, Abdul Rafeh Naqash, Alex F. Herrera
Journal: Blood (2023)
Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study
Authors: Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee
Journal: Blood (2023)
Prospective Identification of Variables As Outcomes for Treatment (PIVOT): A Phase II Clinical Trial of Hydroxyurea for Children and Adults with HbSC Disease
Authors: Catherine I. Segbefia, Luke R. Smart, Susan E. Stuber, Priscilla Ekpale, Kwesi N. Amissah-Arthur, Klenam Dzefi-Tettey, Enoch Mensah, Adam C. Lane, Diana Dwuma-Badu, Teresa S. Latham, Yvonne Dei-Adomakoh, Russell E. Ware
Journal: Blood (2023)
Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium
Authors: Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel
Journal: Blood (2023)
CD70/CD27 Signaling Promotes Expansion of Clonal Plasma Cells in Multiple Myeloma and Is a Promising Therapeutic Target in Advanced Disease
Authors: Stefan Forster, Chantal Bachmann, Maxime Boy, Ramin Radpour, Christian M Schuerch, Frido Brühl, Carsten Riether, Adrian Ochsenbein
Journal: Blood (2023)
Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era
Authors: Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
Journal: Blood (2023)
Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients
Authors: Santiago Thibaud, William Genthe, Saoirse Bodnar, Alessandro Lagana, Jane Houldsworth, Ajai Chari, Adriana C Rossi, Cesar Rodriguez, Larysa J Sanchez, Shambavi Richard, Joshua Richter, Kenan Onel, Sundar Jagannath, Tehilla Brander, Samir Parekh
Journal: Blood (2023)
I-DATA Study: Randomized, Sequential, Open-Label Study to Evaluate the Efficacy of IDH Targeted/Non- Targeted Versus Non-Targeted/IDH-Targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated Adult AML Patients Not Candidates for Intensive Induction Therapy
Authors: Michael P Ozga, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Jill Buss, Andrea Laganson, Ethan Hamp, Yazan F. Madanat, Daniel A. Pollyea, Eytan M. Stein, Joshua F. Zeidner, Elaine R Mardis, Ann-Kathrin Eisfeld, Alice Mims
Journal: Blood (2023)
Sequential Umbilical Cord Derived Mesenchymal Stromal Cells (MSCs) for the Third-Line Salvage Treatment of Steroid-Refractory Acute GvHD: A Multicenter, Open Label, Phase 1b/2 Trial
Authors: Yanmin Zhao, Yi Luo, Jimin Shi, Jian Yu, Lizhen Liu, Xiaoyu Lai, Huarui Fu, Yishan Ye, Nainong Li, Erlie Jiang, Jundong Gu, Zhibo Han, Zhongchao Han, He Huang
Journal: Blood (2023)
High Dimensional Single-Cell Profiling Identifies Immune and Metabolic Heterogeneity in Immune Thrombocytopenia
Authors: Li-Ping Yang, Hai-Xia Fu, Peng Zhao, Jin Wu, Qiu-Sha Huang, Yuan-Yuan Zhang, Jun Kong, Zhi-Dong Wang, Jing Liu, Kaiyan Liu, Xiao Jun Huang, Xiaohui Zhang
Journal: Blood (2023)